Indacaterol/glycopyrrolate Significantly Improves COPD Assessment Test (cat) Scores In Us Patients With Moderate-To-Severe COPD: Subgroup Analysis From Pooled Flight1 And Flight2 Studies

被引：0
|
作者：
Fogel, R. [1 ]
Maitra, S. [2 ]
Patalano, F. [3 ]
Banerji, D. [1 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[3] Novartis Pharma AG, Basel, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6801
引用
收藏
页数：1
相关论文
共 46 条
  • [41] Glycopyrronium Demonstrates Significant Improvements in Lung Function in Patients With Moderate-to-Severe COPD: Pooled Analysis From the GEM1 and GEM2 Studies
    Kerwin, Edward
    Spangenthal, Selwyn
    Miller, S. David
    D'Andrea, Peter
    Henley, Michelle
    Eckert, Joerg H.
    Patalano, Francesco
    CHEST, 2015, 148 (04)
  • [42] Glycopyrronium Improved Health Status, Dyspnea, and Reduced Rescue Medication Use in Patients With Moderate-to-Severe COPD: Pooled Analysis From GEM1 and GEM2 Studies
    Laforce, Craig
    Kerwin, Edward
    Spangenthal, Selwyn
    D'Andrea, Peter
    Henley, Michelle
    Eckert, Joerg H.
    Patalano, Francesco
    CHEST, 2015, 148 (04)
  • [43] Qva149 Shows Rapid Onset Of Bronchodilation Versus Placebo And Its Mono-Components In Patients With Moderate To Severe COPD: Pooled Data From The Flight Studies
    Banerji, D.
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Patalano, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [44] Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials
    Wedzicha, Jadwiga A.
    Buhl, Roland
    Lawrence, David
    Young, David
    RESPIRATORY MEDICINE, 2015, 109 (01) : 105 - 111
  • [45] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [46] Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies
    Yosipovitch, Gil
    Staender, Sonja
    Metz, Martin
    Pink, Andrew E.
    Silverberg, Jonathan, I
    Sofen, Howard
    Ahmed, Faiz
    Noda, Aliene
    Lopez, Zarif K. Jabbar
    Piketty, Christophe
    Kwatra, Shawn G.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 47 - 48
12345